DOCSLIB.ORG

Programme.Final.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Programme.Final.Pdf FACULTY ACADEMY SLEIGHT Peter, Oxford, GBR ABRAHAM William T., Columbus, USA SOBHY Mohamed, Alexandria, EGY ADAMS Kirkwood, Chapel Hill, USA STAELS Bart, Lille, FRA AGEWALL Stefan, Oslo, NOR STROES Eric, Amsterdam, NED AKEHURST Ron, Sheffield, GBR SWYNGHEDAUW Bernard, Paris, FRA ANKER Stefan, Berlin, GER TARDIF Jean-Claude, Montréal, CAN AZIZI Michel, Paris, FRA TAVAZZI Luigi, Cotignola, ITA BAIGENT Colin, Oxford, GBR TAWAKOL Ahmed, Boston, USA BAKRIS George, Chicago, USA TORP-PEDERSEN Christian, Copenhagen, DEN BEYGUI Farzin, Paris, FRA TSCHOEPE Carsten, Berlin, GER BLANKENBERG Stefan, Hamburg, GER VERHEUGT Freek, Amsterdam, NED BORER Jeffrey, New York, USA VOORS Adrian, Groningen, NED BRUTSAERT Dirk L, Antwerp, BEL WACHTER Rolf, Göttingen, GER CALVO Gonzalo, Barcelona, ESP WAHL Denis, Nancy, FRA CASAS Juan Pablo, London, GBR WARNOCK David, Birmingham, USA CHOUDHURY Robin, Oxford, GBR WASSMANN Sven, Munich, GER CLELAND John, Hull, GBR WHEELER David, London, GBR CLEMMENSEN Peter, Copenhagen, DEN WIERZBICKI Anthony, London, GBR COHEN-SOLAL Alain, Paris, FRA ZANNAD Faiez, Nancy, FRA COWIE Martin, London, GBR DAN George-Andrei, Bucharest, ROM DE FERRARI Gaetano, Pavia, ITA EMEA–FDA–NHLBI-PMDA-MHRA DREXEL Heinz, Feldkirch, AUS ANDO Yuki, PMDA, JAP DUNLAP Stephanie, Chicago, USA ALONSO Angeles, EMEA, ESP EZEKOWITZ Justin, Edmonton, CAN BONDS Denise, NHLBI, USA FAYAD Zahi, New York, USA COOK Nakela, NHLBI, USA FELKER Michael, Durham, USA DE GRAEF Pieter, EMEA, NED FIUZAT Mona, Durham, USA DUNDER Kristina, EMEA, SWE GAMRA Habib, Monastir, TUN FARB Andrew, FDA, USA GHEORGHIADE Mihai, Chicago, USA GELLER Nancy, NHLBI, USA GIBSON Michael, Boston, USA GORDON David, NHLBI, USA GIRERD Nicolas, Nancy, FRA HEMMINGS Robert, MHRA, GBR GOLDSMITH David, London, GBR MASCETTE Alice, NHLBI, USA HALLER Hermann, Hannover, GER PRASAD Krishna, MHRA, GBR HARDMAN Suzanna, London, GBR ROSANO Giuseppe, EMEA, ITA HERNANDEZ Adrian, Durham, USA ROSENBERG Yves, NHLBI, USA HOFFMANN Udo, Boston, USA SHINAGAWA Kaori, PMDA, JAP JARCHO John, Boston, USA JANUZZI Jim, Boston, USA KASKI Juan Carlos, London, GBR INDUSTRY KJELDSEN Keld, Copenhagen, DEN ADOURIAN Aram, BG Medicine, USA KJELDSEN Sverre E., Oslo, NOR AUDHYA Paul, Reata, USA KOENIG Wolfgang, Ulm, GER BERKOWITZ Scott, Bayer, USA LEWIS Basil, Haïfa, ISR BUYSSE Jerry, Relypsa, USA LINDE Cecilia, Stockholm, SWE CARLSON Mark, St Jude Medical, USA LOSCALZO Joseph, Boston, USA CODY Robert, J&J, USA MAGGIONI Aldo, Florence, ITA DELIARGYRIS Efthymios, The Medicines Company, USA MAHFOUD Felix, Homburg, GER FRIEDMAN Jeffrey, Boehringer Ingelheim, USA MARRE Michel, Paris, FRA GAUDIN Christophe, Sanofi, FRA MARTINEZ Felipe, Cordoba, ARG GOBBI Giorgio, Medtronic, CHE MASSY Ziad, Boulogne-Billancourt, FRA HASKEL Lloyd, J&J, USA MEBAZAA Alexandre, Paris, FRA HOUDIJK Wim, Biomérieux, FRA MEHRAN Roxana, New York, USA KHDER Yasser, Boehringer Ingelheim, FRA METRA Marco, Brescia, ITA KIEVAL Rob, CVRx, USA NARULA Jagat, New York, USA KIM Jae, Amgen, USA O’CONNOR Christopher, Durham, USA KOGLIN Joerg, Merck, USA PAIS Prem, Bangalore, IND KUPFER Stuart, Takeda, USA PATHAK Atul, Toulouse, FRA LASALVIA Luis, Siemens, USA PEACOCK Frank, Cleveland, USA LAWRENCE John, BMS, USA PFEFFER Marc, Boston, USA MENDELSOHN Michael, Merck, USA PIÑA Ileana, New York, USA MIX Chris, Amgen, USA PITT Bertram, Ann Arbor, USA ROESSIG Lothar, Bayer, GER POCOCK Stuart, London, GBR SCOTT Robert, Amgen, USA RAY Kausik, London, GBR SEMJONOW Véronique, Philips, NED REDBERG Rita, San Francisco, USA SHIPMAN Tami, St Jude Medical, USA ROSENSON Robert, New York, USA SNIDER James, Critical Diagnostics, USA ROSSI Gian Paolo, Padua, ITA STEIN Kenneth, Boston Scientific, USA ROSSIGNOL Patrick, Nancy, FRA TAIEL-SARTRAL Magali, Lilly, FRA ROUSSEL Ronan, Paris, FRA TSOUDEROS Yannis, Servier, FRA RUDD James, Cambridge, GBR VINCENT Alphons, Medtronic, CHE RUILOPE Luis, Madrid, ESP YADAV Jay, CardioMEMS, USA SILVAIN Johanne, Paris, FRA YARED Nadim, CVRx, USA SIMON Tabassome, Paris, FRA WASSERMAN Scott, Amgen, USA SIMOONS Maarten, Rotterdam, NED WOEHRLE Holger, ResMed, GER 2 9th Global CardioVascular Clinical Trialists Forum • Paris 2012 GENERAL PRESENTATION Organized in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy, CVCT Forum is a meeting specifically and totally dedicated to the discussion of clinical trials in cardiovascular disease. CVCT Forum is attended by experts principally engaged in cardiovascular clinical trials (hence it’s name). Participants are among the group of major international opinion leaders and come from various functions linked with primary care, pharmaceutical industry, pharmaceutical regulatory bodies, and publishing houses from around the world (US, Canada, Asia, Europe, and Japan). An outstanding faculty members are committed to disseminating concise data from controlled clinical trials that contribute to better clinical care and to discussing and identifying issues and relevant information. Such as how to do better clinical trials, how to satisfy regulatory authorities, and most importantly, how to improve cardiovascular health care. The CVCT meetings are ‘grass root’ meetings, attended by individuals who are eager to communicate with one another and to share experiences with primary care physicians and the people that create and analyze major trials. CVCT meetings are primarily oriented toward discussion among persons as opposed to lecturing to a broad audience. Thought process counts, communication (during the meeting, but more importantly informal discussions outside of the meeting) is the important agenda, as opposed to dictating doctrine. The format of the meeting is set to fulfill these aims. Beyond plenary sessions the meeting is structured with a variety of small interactive brainstorming workshops, expert discussions and consensus building workshops. The discussion takes place with a selected audience of opinion leaders, clinical trialists, pharmaceutical industry partners, regulators, investigators and cardiologists. CVCT Forum aims to: ■ Familiarize practitioners and young investigators with the science of clinical trials from trial protocol design to trial result interpretation ■ Examine the background of knowledge which led to the design of major trials ■ Identify and understand best evidence from clinical trials ■ Examine the consequences of trial results on the updating of guidelines ■ Consider the consequences and relative weight of Evidence based vs Mechanism based and Marketing based medicine ■ Identify emerging important issues in cardiovascular medicine ■ Examine opportunities and needs for new trials We do hope that you will share with us the excitement of this unique learning experience and we are very happy to welcome you in Paris. Pr. Faiez ZANNAD Dr. Bertram PITT 9th Global CardioVascular Clinical Trialists Forum • Paris 2012 3 SUMMARY SCIENTIFIC PROGRAM PROGRAM AT A GLANCE .......................................................................................... 5 Friday November 30th ....................................................................................................... 6 Saturday December 1st ....................................................................................................... 12 CVCTlive Sessions ............................................................................................................. 20 CVCT YOUNG TRIALISTS MENTORING .................................................................. 22 CVCT RESSOURCE CENTER ..................................................................................... 22 EUROPEAN BOARD FOR ACCREDITATION IN CARDIOLOGY ........................... 22 ENDORSING PARTNERS ............................................................................................ 23 SPEAKERS BIOGRAPHIES & ABSTRACTS .............................................................. 25 POSTERS ...................................................................................................................... 65 GENERAL INFORMATION .......................................................................................... 71 th 4 4 9 th Global 9 Global Cardio CardioVascularVascular Clinical Clinical Trialists Trialists Forum Forum • Paris • Paris 2012 2012 PROGRAM AT A GLANCE FRIDAY NOVEMBER 30, 2012 PARIS / CET 08:00 am - 10:00 am 10:20 am - 12:30 am 12:45 am - 03:15 pm 03:30 pm - 05:00 pm 05:20 pm - 07:30 pm LUNCH DEBATE WORKSHOP 1 WORKSHOP 1 SESSION 1 WORKSHOP 2 WORKSHOP 2 THE THE ATHEROSCLEROSIS ATHEROSCLEROSIS THE DEVICE MODIGLIANI THROMBOSIS THROMBOSIS IMAGING IMAGING THERAPY TRIALISTS TRIALISTS IN CLINICAL IN CLINICAL TRIALISTS TRIALS TRIALS WORKSHOP K WORKSHOP K K WORKSHOP REA REA REA B B B XES SERVED EE EE EE BO COFF LUNCH DEBATE COFF COFF LUNCH SESSION 2 NEW EVIDENCE, WORKSHOP 4 WORKSHOP 4 WORKSHOP 3 WORKSHOP 3 NEW GUIDELINES CARDIOVASCULAR CARDIOVASCULAR SOUTINE / THE DIABETES THE DIABETES & PREVENTION PREVENTION UTRILLO TRIALISTS TRIALISTS FUTURE IN CHRONIC IN CHRONIC WORKSHOP WORKSHOP DEVELOPMENTS WITH IVABRADINE KIDNEY DISEASE KIDNEY DISEASE SATELLITE SYMPOSIUM SATURDAY DECEMBER 1, 2012 PARIS / CET 08:00 am - 10:00 am 10:20 am - 12:30 am 12:45 am - 03:15 pm 03:30 pm - 05:00 pm 05:20 pm - 07:30 pm DEBATE DEBATE WORKSHOP 5 WORKSHOP 5 LUNCH DEBATE SESSION 4 SESSION 5 THE THE SESSION 3 HEART FAILURE MODIGLIANI ATHEROSCLEROSIS ATHEROSCLEROSIS HEART FAILURE NOVEL DIURETIC REMOTE TRIALISTS TRIALISTS TRIALISTS STRATEGIES MONITORING IN HEART FORUM FORUM WORKSHOP k K TRIALS K FAILURE
Load more

Recommended publications
  • An Insertion/Deletion Polymorphism in the Angiotensin I- Converting Enzyme Gene Accounting for Half the Variance of Serum Enzyme Levels
    An insertion/deletion polymorphism in the angiotensin I- converting enzyme gene accounting for half the variance of serum enzyme levels. B Rigat, … , P Corvol, F Soubrier J Clin Invest. 1990;86(4):1343-1346. https://doi.org/10.1172/JCI114844. Research Article A polymorphism consisting of the presence or absence of a 250-bp DNA fragment was detected within the angiotensin I- converting enzyme gene (ACE) using the endothelial ACE cDNA probe. This polymorphism was used as a marker genotype in a study involving 80 healthy subjects, whose serum ACE levels were concomitantly measured. Allele frequencies were 0.6 for the shorter allele and 0.4 for the longer allele. A marked difference in serum ACE levels was observed between subjects in each of the three ACE genotype classes. Serum immunoreactive ACE concentrations were, respectively, 299.3 +/- 49, 392.6 +/- 66.8, and 494.1 +/- 88.3 micrograms/liter, for homozygotes with the longer allele (n = 14), and heterozygotes (n = 37) and homozygotes (n = 29) with the shorter allele. The insertion/deletion polymorphism accounted for 47% of the total phenotypic variance of serum ACE, showing that the ACE gene locus is the major locus that determines serum ACE concentration. Concomitant determination of the ACE genotype will improve discrimination between normal and abnormal serum ACE values by allowing comparison with a more appropriate reference interval. Find the latest version: https://jci.me/114844/pdf Rapid Publication An Insertion/Deletion Polymorphism in the Angiotensin I-converting Enzyme Gene Accounting for Half the Variance of Serum Enzyme Levels Brigitte Rigat, Christine Hubert, Francois Alhenc-Gelas, Franmois Cambien,* Pierre Corvol, and Florent Soubrier Institut National de la Sante et Recherche Medicale U 36, College de France, 75005 Paris; and *INSERJM U 258, 75014 Paris, France Abstract epithelial cells as well as in a circulating form in biological fluids, such as plasma and amniotic or seminal fluids.
    [Show full text]
  • Facts and Data
    FACTS AND D ATA COLLÈGE DE FRANCE ORGANIZATION CHART Administrator of the Collège de France: Pierre CORVOL The Administrator of the Collège de France is a Collège de France professor, elected by his/her colleagues to direct the institution for a period of 3 years. Professors of the Collège de France I – MATHEMATICAL, PHYSICAL AND NATURAL SCIENCES ❍ Analysis and Geometry — Alain CONNES ❍ Differential Equations and Dynamical Systems — Jean-Christophe YOCCOZ ❍ Partial Differential Equations and Applications — Pierre-Louis LIONS ❍ Number Theory — Don ZAGIER ❍ Quantum Physics — Serge HAROCHE ❍ Mesoscopic Physics — Michel DEVORET ❍ Physics of Condensed Matter — Antoine GEORGES ❍ Elementary Particles, Gravitation and Cosmology — Gabriele VENEZIANO ❍ Climate and Ocean Evolution — Édouard BARD ❍ Observational Astrophysics — Antoine LABEYRIE ❍ Chemistry of biological processes — Marc FONTECAVE ❍ Chemistry of Molecular Interactions — Jean-Marie LEHN ❍ Human Genetics — Jean-Louis MANDEL ❍ Genetics and Cellular Physiology — Christine PETIT ❍ Biology and Genetics of Development — Spyros ARTAVANIS-TSAKONAS ❍ Morphogenetic Processes — Alain PROCHIANTZ ❍ Molecular Immunology — Philippe KOURILSKY ❍ Microbiology and infectious diseases — Philippe SANSONETTI ❍ Experimental Cognitive Psychology — Stanislas DEHAENE ❍ Physiology of Perception and Action — Alain BERTHOZ ❍ Experimental Medicine — Pierre CORVOL ❍ Historical Biology and Evolutionism — Armand de RICQLÈS ❍ Human Paleontology — Michel BRUNET II – HUMAN AND SOCIAL SCIENCES ❍ Pharaonic Civilization:
    [Show full text]
  • Lack of Angiotensin II–Facilitated Erythropoiesis Causes Anemia in Angiotensin-Converting Enzyme–Deficient Mice
    Lack of angiotensin II–facilitated erythropoiesis causes anemia in angiotensin-converting enzyme–deficient mice Justin Cole, … , Pierre Corvol, Kenneth E. Bernstein J Clin Invest. 2000;106(11):1391-1398. https://doi.org/10.1172/JCI10557. Article While nephrologists often observe reduced hematocrit associated with inhibitors of angiotensin-converting enzyme (ACE), the basis for this effect is not well understood. We now report that two strains of ACE knockout mice have a normocytic anemia associated with elevated plasma erythropoietin levels. 51Cr labeling of red cells showed that the knockout mice have a normal total blood volume but a reduced red cell mass. ACE knockout mice, which lack tissue ACE, are anemic despite having normal renal function. These mice have increased plasma levels of the peptide acetyl-SDKP, a possible stem cell suppressor. However, they also show low plasma levels of angiotensin II. Infusion of angiotensin II for 2 weeks increased hematocrit to near normal levels. These data suggest that angiotensin II facilitates erythropoiesis, a conclusion with implications for the management of chronically ill patients on inhibitors of the renin-angiotensin system. Find the latest version: https://jci.me/10557/pdf Lack of angiotensin II–facilitated erythropoiesis causes anemia in angiotensin-converting enzyme–deficient mice Justin Cole,1 Dilek Ertoy,1 Hsinchen Lin,1 Roy L. Sutliff,1 Eric Ezan,2 Tham T. Guyene,2 Mario Capecchi,3 Pierre Corvol,2 and Kenneth E. Bernstein1 1Department of Pathology, Emory University, Atlanta, Georgia, USA 2Institute National de la Santé et de la Recherche Medicale Unit 36, College de France, Paris, France 3Howard Hughes Medical Institute, Eccles Institute of Human Genetics, University of Utah, Salt Lake City, Utah, USA Address correspondence to: Ken Bernstein, Room 7107A WMB, Department of Pathology, Emory University, Atlanta, Georgia 30322, USA.
    [Show full text]
  • The Tissue Renin–Angiotensin System in Human Pancreas
    317 The tissue renin–angiotensin system in human pancreas M Tahmasebi1, J R Puddefoot1, E R Inwang2 and G P Vinson1 1Division of Biomedical Sciences, Queen Mary & Westfield College, Mile End Road, London E1 4NS, UK 2Breast Unit, Royal Hospitals Trust, London E1 1BB, UK (Requests for offprints should be addressed toGPVinson, Department of Biochemistry, Queen Mary & Westfield College, Mile End Road, London E1 4NS) Abstract Evidence exists for the presence of a discrete tissue and in endothelial cells of the pancreatic vasculature. renin–angiotensin system (RAS) in mouse and rat pancreas Transcription of (pro)renin mRNA, however, was con- that is thought largely to be associated with the vascu- fined to connective tissue surrounding the blood vessels lature. To investigate this in the human pancreas, and to and in reticular fibres within the islets. These findings are establish whether the cellular sites of RAS components similar to those obtained in other tissues, and suggest that include the islets of Langerhans, we used immunocyto- renin may be released from its sites of synthesis and taken chemistry to localise the expression of angiotensin II (AT1) up by possible cellular sites of action. receptors and (pro)renin, and non-isotopic in situ hybrid- The results presented here suggest that a tissue RAS isation to localise transcription of the (pro)renin gene. may be present in human pancreas and that it may directly Identification of cell types in the islets of Langerhans was affect beta cell function as well as pancreatic blood achieved using antibodies to glucagon and insulin. flow. The results show the presence of the AT1 receptor and Journal of Endocrinology (1999) 161, 317–322 (pro)renin both in the beta cells of the islets of Langerhans, Introduction (Small et al.
    [Show full text]
  • Rapid Publication
    Rapid Publication An Insertion/Deletion Polymorphism in the Angiotensin I-converting Enzyme Gene Accounting for Half the Variance of Serum Enzyme Levels Brigitte Rigat, Christine Hubert, Francois Alhenc-Gelas, Franmois Cambien,* Pierre Corvol, and Florent Soubrier Institut National de la Sante et Recherche Medicale U 36, College de France, 75005 Paris; and *INSERJM U 258, 75014 Paris, France Abstract epithelial cells as well as in a circulating form in biological fluids, such as plasma and amniotic or seminal fluids. The A polymorphism consisting of the presence or absence of a mechanisms leading to the biosynthesis of the circulating form 250-bp DNA fragment was detected within the angiotensin of ACE are still unclear, but all the data available indicate that I-converting enzyme gene (ACE) using the endothelial ACE its structures is very similar to that of the cellular form (3). cDNA probe. This polymorphism was used as a marker geno- Plasma ACE measurement is widely used for the diagnosis type in a study involving 80 healthy subjects, whose serum and follow-up of sarcoidosis because an elevation of the en- ACE levels were concomitantly measured. Allele frequencies zyme is often observed in this disease (4). Although plasma were 0.6 for the shorter allele and 0.4 for the longer allele. A ACE concentrations are remarkably stable when measured re- marked difference in serum ACE levels was observed between peatedly in a normal subject, large interindividual differences subjects in each of the three ACE genotype classes. Serum make it difficult to interpret plasma ACE levels in a given immunoreactive ACE concentrations were, respectively, patient, as the reference interval for normal values is large (5).
    [Show full text]
  • 4 of the Collège De France
    The Letter 4 of the Collège de France N°4 Academic year 2008-2009 Teaching research in the making The Collège de France was created in 1530 by François I The Collège’s motto is « Docet omnia »: the vocation to teach everything The lectures are open to anyone, there are no registration fees, no diplomas are awarded The program is changed each year Dissemination of knowledge - Lectures, seminars, guest lecturers from abroad, international and multidisciplinary conferences: attended by 120,000 people annually - Publications: abstracts of work under way (Yearbook), Inaugural lectures, reopening symposiums and guest professors' lectures, DVDs Website in French and English (www.college-de-france.fr) (4,500 visits/day), Podcasts (3,350,000 downloads/month), audio and video retransmissions - Lectures broadcast by France-Culture (800,000 listeners/month) 57 chairs - 52 Chairs + 5 Chairs renewed annually (Artistic Creation, Information Technology and Digital Sciences, Knowledge against Poverty, Sustainable Development - Environment, Energy and Society, Technological Innovation - Liliane Bettencourt) - Promoting the emergence of new disciplines - Multidisciplinary approach to cutting-edge research - Creation of a new Chair in the scientific domain of every nominated professor (Mathematics, Physics and Chemistry, Biology and Medicine, Philosophy, Sociology, Economics, Archaeology, History, Study of the great civilizations, Linguistics and Literature) International relations - Lectures ans conferences delivered abroad - The professors may deliver
    [Show full text]